Afimkibart

N/A

Report date: 2026/05/23 20:00:57
First In Class

Base Information

Drug NameAfimkibart
Drug Alias NamePF-06480605PF 6480605RVT-3101RG-6631RO-7790121
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTumor necrosis factor superfamily member 15 inhibitors
TargetsTumor necrosis factor superfamily member 15
Therapy Area/IndicationsDermatitis, AtopicMetabolic Dysfunction-Associated Steatotic Liver DiseaseCrohn Disease +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[42] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharmaceutical Co LtdPfizer IncF. Hoffmann-La Roche Ltd +[5] 
Inactive CompaniesTelavant Inc
Active IndicationsDermatitis, AtopicMetabolic Dysfunction-Associated Steatotic Liver DiseaseCrohn Disease +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A